Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models

Abstract

The aim of this study was to characterize the different phenotypes of osteosarcoma by PET, comparing the uptake of 3 tracers ( 18 F-FDG, 18 F-fluoromisonidazole [ 18 F-FMISO], and 18 F-fluoride) in preclinical mouse models that reflect the heterogeneity of the human disease. Methods: Mouse LM8 osteosarcoma, human 143B, and Caprin-1 stably overexpressing SaOS-2 cells were injected intratibially in C3H and severe-combined immunodeficient mice. PET imaging with 18 F-FDG, 18 F-FMISO, and 18 F-fluoride was performed in these mouse models, and a ratio between the standardized uptake value of the primary tumor and a control area of bone was calculated and compared among the models. Histology and immunohistochemistry were performed to confirm the PET findings. Results: The pattern of tracer uptake differed among the primary tumors of the 3 models in accordance with the histology and immunohistochemistry on primary tumor sections. The osteolytic tumors in the 143B model showed the highest uptake of 18 F-FDG, an indicator of glucose metabolism, which was significantly higher (P , 0.05) than in the SaOS-2/Caprin-1 model and correlated with the percentage of Ki67-positive cells in the primary tumors. Hypoxia, indicated by 18 F-FMISO accumulation, was higher in the SaOS-2/ Caprin-1 and 143B cell line-derived tumors (P , 0.01). Finally 18 Ffluoride, a marker of bone remodeling, correlated with the osteoblastic phenotype. The SaOS-2/Caprin-1 cell-derived tumors showed a significantly higher uptake than the moderately osteoblastic LM8 (P , 0.05) and the osteolytic 143B (P , 0.01) cell line-derived tumors. Conclusion: Differential PET imaging with tracers indicating metabolic activity, hypoxia, or bone remodeling will be helpful for the characterization of different osteosarcoma phenotypes and subsequent evaluation of more specific treatment modalities targeting the processes that are predominant in each specific tumor type or subtype.

A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep

“…18 F, as a radiotracer, was shown to accumulate in a lung metastasis of an osteogenic sarcoma [121]. These results were consistent with Campanile's study, indicating bone remodeling and tumor targeting of 18 F-fluoride in PET imaging [122]. This suggests the possibility of bone-targeting fluoride-modified NPs in PDT.…”

18F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma

“…In a preclinical mouse model, different phenotypes of OS were demonstrated with 3 different radiotracers: 18 F-FDG, 18 F-fluoromisonidazole, and 18 F-fluoride (23). 18 F-FDG uptake was higher in osteolytic lesions, and 18 F-fluoromisonidazole and 18 F-fluoride uptake were higher in osteoblastic lesions (23). Such disease characterization provides the framework for the further evaluation of tumor biology to determine a treatment response.…”

Positron emission tomography to assess hypoxia and perfusion in lung cancer

“…Bentzen et al [195] , Rasey et al [196] , Bentzen et al [197] , Troost et al [198] Bentzen et al [125] , Gagel et al [126] , Bruehlmeier et al [199] , Lawrentschuk et al [200] , O'Donoghue et al [72] , Piert et al [166] , Sørensen et al [201] , Gagel et al [202] , Carlin et al [203] , Chang et al [204] , Mortensen et al [127] Hatano et al [205] , Huang et al [206] , Huang et al [207] , Oehler et al [208] , Cho et al [209] , Troost et al [210] , Matsumoto et al [136] , Troost et al [198] , Dubois et al [211] Dubois et al [211] , Cherk et al [212] , Riesterer et al [213] , Lehmann et al [214] , Chen et al [215] , Campanile et al [216] , Cheng et al [217] , Sato et al [218] , Norikane et al [219] Cherk et al [212] , Eschmann et al [77] , Gagel et al [82] , Koh et al [87] , Rasey et al [220] , Vera et al…”